EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)
- Monday, July 19, 2021, 7:17
- PR Newswire
- Add a comment
CHARLESTON, S.C. and COPENHAGEN, Denmark, July 19, 2021 /PRNewswire/ — EPI Health and MC2 Therapeutics, announced today commercial availability in the United States of Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for the topical treatment of plaque…
About the Author
admin has written 20951 stories on this site.